Tagrisso Osimertinib — Highmark
5 indications indexed for this drug.
- First Line Metastatic NsclcView coverage criteria
- Locally Advanced Or Metastatic Nsclc In Combination With PemView coverage criteria
- Locally Advanced Unresectable Stage Iii NsclcView coverage criteria
- Metastatic Egfr T790m Mutation Positive NsclcView coverage criteria
- Nsclc Adjuvant After Tumor ResectionView coverage criteria